| |
|
|
| Year : 2006 | Volume
: 17
| Issue : 4 | Page : 190-198 |
|
| Pentoxifylline therapy : A new adjunct in the treatment of oral submucous fibrosis |
|
|
R Rajendran, Vidya Rani, Saleem Shaikh
Department of Oral Pathology & Microbiology, Govt Dental College, Trivandrum 695 001, Kerala, India
Click here for correspondence address and email
|
|
 |
|
 Abstract | | |
OBJECTIVE : This study was designed to determine the effect of pentoxifylline (Trental) on the clinical and pathologic course of oral submucous fibrosis. This drug is a methylxanthine derivative that has vasodilating properties and was envisaged to increase mucosal vascularity. STUDY DESIGN : This investigation was conducted as a randomized clinical trial incorporating a control group (Standard drug group SDG, multivitamin, and local heat therapy) in comparison to pentoxifylline test cases (Experimental drug group EDG, 400mg 3 times daily, as coated, sustained release tablets). The stipulated treatment period was 7 months and a total of 29 cases of advanced fibrosis (14 test subjects and 15 age and sex matched diseased controls) were included in this study and 100% compliance was reported at the end ofthe test period. RESULTS : Mild gastric irritation that could be managed by diet protocols was the only untoward symptom reported during this trial. Review of the patients and controls was done at an interval of 30 days and subjective and objective measurements were recorded. The follow up data at each visit with respect to each other and to base-line values was calibrated using a nonparametric test of Mann-Whitney (Kruskal-Wallis test). Significant comparisons with regard to improvement were recorded as objective criteria of mouth opening (t=11.285, p= 0.000), tongue protrusion (t= 3.898, p = 0.002), and relief from perioral fibrotic bands (p = 0.0001554). Subjective symptoms of intolerance to spices (p = 0.0063218), burning sensation of mouth (p = 0.0005797), tinnitus (p=0.000042), difficulty in swallowing (p=0.0000714). and difficulty in speech (p=0.0000020) were also recorded significant improvement at the end of the trial period. CONCLUSION : This pilot investigation points to the effectiveness of pentoxifylline as an adjunct therapy in the routine management of oral submucous fibrosis. Keywords: Pentoxifylline, Trental, oral submucous fibrosis, treatment
How to cite this article:
Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy : A new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res 2006;17:190-8 |
How to cite this URL:
Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy : A new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res [serial online] 2006 [cited 2023 Jun 5];17:190-8. Available from: https://www.ijdr.in/text.asp?2006/17/4/190/29865 |
| Introduction | |  |
Oral submucous fibrosis (OSF) remains enigmatic and characterization of its pathogenesis is still met with difficulties, caused primarily due to the inability to prove a cause-effect relationship in ascribing any known agent in its causation. The fibrogenic potential of areca- nut alkaloids and tanning had been studied extensively and was proved to have an effect in its causation, backed with epidemiological and experimental evidences [1]. But this remains inconclusive against the backdrop of clinical cases, sizable in proportion, of patients who refrain from any such habits [2]. The reality of "non-arecanut cases" cannot be overlooked and the majority of investigators now uphold the multifactorial origin of this disorder with probable genetic predisposition in its causation. This uncertainty as regards its causation is reflected primarily in its management protocols and it, still at best, remains empirical.
The degree of vascularity of the diseased mucosa in OSF has always been a matter of dispute while good casecontrol studies on the integrity and patency of microvasculature still lacking. Histological evidence goes against the concept of decreased vascularity and the often reported epithelial "atrophy" in OSF is based on the assumption of an ischemic epithelium resultant to poorly vascularised stroma. The atrophic epithelium is envisaged to pre-dispose to malignant transformation when brought in contact with oral carcinogens.
The objective of this clinical study was to evaluate the efficacy of pentoxifylline, a methylxanthine derivative, that has vasodilating properties and may decrease platelet aggregation on the clinical and pathologic course of this disease. This controlled investigation was carried as a randomized clinical trial incorporating a control group (multi-vitamin and localized heating protocols) in comparison with pentoxifylline (400mg thrice daily) administered in the form of coated sustained release tablets.
| Patients and methods | | |
Study design and sample
The study comprised a prospective clinical analysis of 29 randomly selected OSF patients, graded as clinically advanced, judged by established clinico-pathologic parameters and evaluated in randomized clinical trial. All the patients recruited to the study were of comparable disease progression and share the common demographic features of ethnicity , geographic localization, and socioeconomic status and all of them were habitual chewers of 'areca-quid'. The patient stock was fragmented into experimental drug group (EDG, n=14) where the active treatment option was pentoxifylline, (Trental asub 400mg tablets) and the standard drug group (SDG, n=15) was managed with multi-vitamin capsules (one capsule before sleep daily). Local heating therapy (hot water exercise and forceful mouth opening) was practiced uniformly by both the groups of patients. The EDG before administration of pentoxifylline, underwent detailed hematological and clinical tests to rule out systemic ailments of hypertension, diabetes mellitus, cardiac diseases, malignant ulcers, duodenal and gastric peptic ulcers, bleeding diatheses, and the like. The hematological work up comprised recording of total leukocyte count (TC), differential count (DC), hemoglobin values (Hb), platelet count (PC), clotting and bleeding times (CT, BT), recordings of blood pressure (systolic and diastolic), and pulse characters of the patients.
The drug pentoxifylline was administered as an inductive regime for the initial 30 days at a reduced dosage of 2 tablets daily and at the end of the period, all the test cases underwent routine blood and systemic examinations to record untoward effect(s), if any. Thereafter the dose was hiked to 3 tablets daily (400mg) for all the patients in the EDG. The drop out figure recorded was zero and the clinical symptoms reported were mild gastritis and gastric irritation, peripheral flushing, and warmth of upper trunk, that could be managed easily. One patient who complained of continued gastric irritation was dropped from the EDG after the induction period of one month. No other reportable complications or side effects were recorded from any of the patients included in the study design and the clinical trial was carried out further for 6 more months (total of 7 months). Clinical follow up and review of all the patients included in the EDG and SDG was carried out at 30 days intervals for the whole trial period of 7 months. During each visit, recordings to evaluate the objective and subjective improvement from disease of both the groups were assessed and scored and entered in a specially designed' proforma' drawn for the purpose. To prevent bias due to interpersonal variability, the same investigator (RR) measured all the patients during each visit (all the measurements were recorded in centimeters).
Study variables
The clinical recordings were made under two headings during each visit:
a) Objective:
- Improvement in mouth opening (measurement in centimeters of inter- incisal / alveolar clearance),
- Tongue protrusion (measurement in centimeters from the reference point of lip vermillion)
- Relieffrom fibrotic bands (digitalpalpation)
b) Subjective:
- Relief from intolerance to spicy food
- Relief from burning sensation
- Improvement in salivation, mucosal rigidity, depapillation of tongue
- Relief from tinnitus (ringing in the ear)
- Relief from difficulty in swallowing (especially of solid food)
- Relief from difficulty of speech (phonation)
Statistical comparision of EDG and SDG at each visit with respect to each other and to base-line values (pretreatment measurements) was done using a non parametric test of Mann Whitney (Kruskal Wallis test).
Follow up period
All the patients included in this clinical trial are at different stages of follow up; the period ranges from 6 months to one year after cessation of active medication. The base-line therapy of localized heating and mouth exercise continues until the time of this reporting.
| Results | | |
Baseline data
Age and Sex
The mean age of the patients in the study group was 39.64±7.2years and that of the controls was 41.13 ± 5.51 (t = -0.62, p = 0.54, NS). The male to female ratio of the study group was 9:5 and that of the control group was 9:6 (X 2 = 0.02, p=0.88, NS). Therefore both the patient groups were comparable with respect to age and sex ratio.
Assessment of objective criteria of disease progression measured at interval of 30 days
1) Improvement in mouth opening
(V= number of visit, d= the relative difference between visits) in inter-incisal / alveolar clearance recorded between the follow up visits (of 30 days) of study and control groups of patients with respect to base-line values was analyzed using the test of Mann Whitney (Kruskal Wallis test). The comparisons made were highly significant for all the visits [Table - 1]
2) Improvement in tongue protrusion base-line reference to vermillion lip
The relative difference in tongue protrusion was compared between study and control groups at each visit with respect to base-line value using modified 't' test. The comparisons were erratic with significant levels achieved during V5 and V6 visits. When analyzed separately the test cases recorded better overall improvement when compared to control [Table - 2]
3) Relief from fibrotic bands (Peri-oral, anterior and posterior buccal mucosa, junction of hard and soft palate)
The values recorded and the comparisons made were inconsistent and therefore rated as 'inconclusive'. The patients who reported no palpable bands at the perioral location at first visit (n = 7) were not included in the analysis. The relief from perioral and buccal mucosal fibrous bands reported at the end of the clinical trial in EDG was highly significant (p = 0.000 1554). [Table - 3],[Table - 4],[Table - 5],[Table - 6]
Assessment of subjective criteria
All the subjective symptoms were recorded on a scale of 0-2, based on severity. Any improvement in the severity of symptoms when compared to initial visit was considered to be `improved', and the rest `non improved'. Chi-square test / Fisher's exact test was used wherever appropriate.
1) Relief from intolerance to spicy food
Comparison of improvement (based on interview data) in the symptom was made at each visit between EDG and SDG and recorded as 'highly significant'. 'Spicy food' denotes seasoning with red chilly, a common culinary item of the area. [Table - 7]
2) Relief from' burning mouth'
Comparison of improvement of the symptom was made at each visit between EDG and SDG. The comparisons were 'highly significant' in all the visits. [Table - 8]
3) Improvement in salivation, rigidity of the mucosa and de-papillation of dorsum tongue
The values recorded were erratic and the effect of the drug was assessed to be `inconclusive'. [Table - 9],[Table - 10],[Table - 11].
4) Improvement from tinnitus ('ringing in the ear')
Comparisons were 'highly significant' statistically in all the visits [Table - 12].
5) Improvement from difficulty in swallowing, speech
The comparisons were 'highly significant' in all the visits. [Table - 13],[Table - 14]
| Discussion | | |
Pentoxifylline is a tri-substituted methylxanthine derivative, the biologic activities of which are numerous. This includes increasing red cell deformability, leukocyte chemotaxis, antithrombin and anti- plasmin activities, and more importantly to the present context, its fibrinolytic activity. Pentoxifylline decreases red cell and platelet aggregation, granulocyte adhesion, fibrinogen levels, and whole blood viscosity [3]. Recent work has delineated pentoxifylline's ability to decrease production of tumor necrosis factor alpha and reduce some of the systemic toxicities mediated by interleukin-2 [4],[5],[6]. These two cytokines are important mediators of the inflammatory response. In addition, pentoxifylline has been shown to increase the production of PGE2 and PGI2 by vascular epithelium, important in maintaining cellular integrity and homeostasis after acute injury [7],[8],[9]. Because this drug has proved effective in treating intermittent claudication caused by chronic peripheral arterial occlusion, we surmised that it might also be effective in treating OSF, having a putative association with mucosal ischemia and resultant epithelial atrophy. The submucosal fibrosis, which is the hallmark of the disorder, is envisaged to be the result of a defective inflammatory reparative response culminating in fibrotic healing [10].
The degree of vascularity of the diseased mucosa in OSF has always been a matter of dispute. While good case control studies on the integrity and patency of microvasculature of the mucosa in OSF are still lacking, histological evidence goes against the concept of decreased vascularity in this disease [11]. An evidence in support of this was the recent demonstration of the status of vascular patency in OSF, by image analysis (OPTIMAS ver 6.0), that the mean vascular luminal diameter recorded an increasing trend as the disease progresses (Rajendran et al. unpublished observation). This was a significant conceptual deviation from the common wisdom, as regards to the pathogenesis of this disease. Against this backdrop the concept of ischemic atrophy was disputed by these authors who held that the usual tissue reaction resultant to ischemia / hypoxia does not seem to operate in this disease; which is preconditioned by significant stromal changes as part of the disease process. These authors demonstrated a mean vascular dilatation, instead of a generalized vasoconstriction, which they assumed to be an adaptive response to tissue ischemia due to the physical effects of pathological fibrosis. It is speculative therefore to evaluate the role of a peripheral vasodilator pentoxifylline, in the treatment of OSF. The beneficial effect recorded by pentoxifylline in managing advanced OSF, prompt us to explore further with the biological effects of this drug, and also to elucidate the effectiveness of this drug in dealing with this rather prototype of pathologic fibrosis.
Because OSF is a chronic mucosal inflammatory disease (persistent stomatitis and glossitis), control of the inflammation or the factors influencing the inflammatory process should form the basis of definitive management. Primary immunologic abnormalities have been reported with OSF and that these immune abnormalities probably mediate local tissue damage and that they appear to be the final common pathway in the pathogenesis of OSF. But there is no unifying explanation for this immunological basis of OSF [12]. The drug pentoxifylline is said to have the property of suppressing leucocyte function while altering fibroblast physiology and stimulating fibrinolysis. Its immuno-modulating actions include increasing leucocyte adhesion. It also causes neutrophil degranulation and the release of peroxides, promotes natural killer cell activity and the production of tumor necrosis factor, and inhibits T and B cell activation [13]. The subjective improvement in clinical outcome recorded in this study may probably be attributed to these pharmacological effects of the drug. The anti inflammatory and immunomodulatory actions of'Trental' seems to have definite therapeutic advantages in the management of OSF but the long term effects of which is difficult to speculate now. Some of our patients are being followed up for a period of more than 12 months and the beneficial effects seemed to be holding, is regarded as a desirable effect of the drug.
The property of pentoxifylline that may be far-reaching in the management of OSF is perhaps its effect on the fibroblast and the role it assumed in fibrinolysis. There are some features exclusive to skin and the subcutaneous tissue that may also be important in the oral mucosal sites, particularly in the context of wound healing and connective tissue diseases in general. Berman and Duncan (1989) [14] showed that fibroblasts cultured in the presence of pentoxifylline produce twice as much collagenase activity and decreased amount of collagen, glycosaminoglycans and fibronectins. IL-1 induced fibroblast proliferation was inhibited by the addition of pentoxifylline. In another series by Berman et al (1992) [15] pentoxifylline blocked TNF-a induced synthesis of fibroblast collagen, glycosaminoglycans and collagenolytic activity. It was determined that these selective inhibitory effects occurred without altering TNF-a receptor mRNA, the number of cell receptors, or affinity for TNF-a receptors compared with untreated controls. These results suggest that the inhibitory activities of pentoxifylline on fibroblasts are mediated at a locus other than TNF-a receptors.
Most side effects caused by pentoxifylline involve the gastrointestinal tract and central nervous system. In initial placebo-controlled clinical trials, the overall incidence of adverse effects was higher in patients who received pentoxifylline in capsule form than in those who received a commercially available sustained release tablet (SRT) [3]. The latter formulation slows drug delivery and minimizes gastric intolerance. The most frequent gastrointestinal complaints include dyspepsia, nausea and /or vomiting in less then 3% of the patients receiving 1200mg per day in sustained release form. Approximately 1% report bloating, flatus, and bleeding. Principal central nervous system side effects include dizziness and headache in a small percentage of patients, whereas tremor, anxiety, and confusion occur in some. Both central nervous system and gastro-intestinal side effects are dose related and are therefore minimized by dose reduction. The adverse side effects which warrant ceasation of therapy occurred in only one patient in this clinical trial and this low frequency of untoward effects was attributed mainly to adherence to the threshold dosage and SRT form of medication.
Although primary or adjunctive therapy with pentoxifylline has been suggested for a multitude of disorders that include cases of pathological fibrosis, there are few controlled clinical trials to confirm its efficacy. It is hoped that future double blind placebo- controlled clinical studies that use pentoxifylline and its derivatives will determine if the many beneficial pharmacokinetic properties of pentoxifylline are effective in treating this enigmatic human disease of oral submucous fibrosis.
| Acknowledgment | | |
The authors would like to acknowledge with gratitude the discussion held on this topic with Dr. Bobby Collins, University of Pittsburgh, United States, which paves way for this clinical trial. The statistical help by way of analysis and interpretation of raw clinical data done by Mr. S. M. Nair, Clinical Epidemiology Unit, Medical College Hospital, Trivandrum is gratefully acknowledged.
| References | | |
| 1. | Murti PR, Bhonsle RB, Gupta PC, Daftary Dr., Pindborg JJ, Mehta FS: Etiology of oral submucous fibrosis with special reference to the role of areca nut chewing, J Oral Pathol Mod 24:145-52,1995.  |
| 2. | Seedat HA, van Wyk CW: Betel-nut chewing and submucous fibrosis in Durban, S Afr Med J 74: 56871, 1988. |
| 3. | Ward A, Clissold SP: Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy, Drug Eval 34: 50-97, 1987. |
| 4. | Edwards MJ, Abney DL, Miller FN: Pentoxifylline inhibits interleukin-2 induced leukocyte-endothelial adherence and reduces systemic toxicity, Surg 110: 199-204,1991. |
| 5. | Han J, Thompson P, Beutler B : Dexamethasone and pentoxifylline inhibit endotoxin induced cachectin / tumor necrosis factor synthesis at separate points in the signalingpathway, J Exp Med 172:391-4,1990. |
| 6. | Streiter RM, Remick DG, Ward PA et al: Cellular and molecular regulation of tumor necrosis factor alpha production by pentoxifylline, Biochem Biophys Res Comm 155:1230-6, 1988. |
| 7. | Fahr A, Langer R, Ziegoleit S: Influence of pentoxifylline administered in-vivo on the synthesis of prostacyclin in human varicose veins, Biomed BiochemActa 14:29,1988. |
| 8. | Hard WH, Herndon DN, Wolfe RR: Kinin /prostaglandin system: its therapeutic value in surgical stress, Crit Care Med 18:1167-74, 1990. |
| 9. | Matzky R, Darins H, Sehroar K: The release of prostacyclin by pentoxifyline from human vascular tissue, Arzneimittelforschung 32: 1315-8, 1982. |
| 10. | Rajendran R, Vijayakumar T, Vasudevan DM: An alternative pathogenetic pathway for oral submucous fibrosis, Med Hypothesis 30: 35-7, 1989. |
| 11. | Rajendran R, Sunil S, Twinkle SP, Anil Kumar TV, Annie J: Cell death does not herald epithelial involution ('atrophy) in oral submucous fibrosis: a TEM study, hid J Dent Res 15(1):13-9,2004. |
| 12. | Chiang CP, Hsieh RP, Chen TH et al: High incidence of autoantibodies in Taiwanese patients with oral submucous fibrosis, J Oral Pathol Med 31: 402-9, 2002. |
| 13. | Samlaska CP, Winfield EA: Pentoxifylline- Clinical review, JAmAcad Dermatol 30:603-21,1994. |
| 14. | Berman B, Dunken MR: Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycans, and fibronectin production, and increases collagenase activity, JlnvestDermatol92:605-10,1989. |
| 15. | Berman B, Wietzerbin J, Sancean J et al: Pentoxifylline inhibits certain constitutive and tumor necrosis factor-a induced activities of human normal dermal fibroblasts, J Invest Dermatol 98: 706-12,1992. |
Correspondence Address:
R Rajendran
Department of Oral Pathology & Microbiology, Govt Dental College, Trivandrum 695 001, Kerala
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0970-9290.29865
Figures
[Figure - 1], [Figure - 2], [Figure - 3] Tables
[Table - 1], [Table - 2], [Table - 3], [Table - 4], [Table - 5], [Table - 6], [Table - 7], [Table - 8], [Table - 9], [Table - 10], [Table - 11], [Table - 12], [Table - 13], [Table - 14] |
|
| This article has been cited by | | 1 |
Comparative Effectiveness of Medicinal Interventions for Oral Submucous Fibrosis: A Network Meta-Analysis. |
|
| Arpita Rai, Priyanshu Kumar Shrivastava, Ansul Kumar, Amit Kumar, Kameshwar Prasad, Saman Shakeel, Zeya ul Haque | | Journal of Stomatology, Oral and Maxillofacial Surgery. 2023; : 101423 | | [Pubmed] | [DOI] | | | 2 |
Heterogeneity of outcome measures in the clinical trials of treatment for oral submucous fibrosis—Systematic review |
|
| Shailesh M. Gondivkar, Monal Yuwanati, Sachin C. Sarode, Amol R. Gadbail, Rima S. Gondivkar | | Oral Diseases. 2022; | | [Pubmed] | [DOI] | | | 3 |
Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases |
|
| Si-Nan Lin, Ren Mao, Chenchen Qian, Dominik Bettenworth, Jie Wang, Jiannan Li, David H. Bruining, Vipul Jairath, Brian G. Feagan, Min-Hu Chen, Florian Rieder | | Physiological Reviews. 2022; 102(2): 605 | | [Pubmed] | [DOI] | | | 4 |
In-vitro analysis on the potential use of dental pulp mesenchymal stem cells on arecoline-induced oral epithelial cells |
|
| Archana A. Gupta, Supriya Kheur, Saranya Varadarajan, Chandini Rajkumar, Vikrant R. Patil | | Medical Oncology. 2022; 39(5) | | [Pubmed] | [DOI] | | | 5 |
Evaluation of Clinical Profile and Various Treatment Modalities in Oral Sub Mucous Fibrosis in North India: Our Experience |
|
| Pankaj Kumar Verma, Amit Kumar Rana, Swati Tripathi, Shivesh Kumar, Deepak Upadhyay | | Indian Journal of Otolaryngology and Head & Neck Surgery. 2022; | | [Pubmed] | [DOI] | | | 6 |
Nanoparticulate strategies for the delivery of miRNA mimics and inhibitors in anticancer therapy and its potential utility in oral submucous fibrosis |
|
| Jyothsna Manikkath, Padacherri Vethil Jishnu, Peter R Wich, Aparna Manikkath, Raghu Radhakrishnan | | Nanomedicine. 2022; | | [Pubmed] | [DOI] | | | 7 |
Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer |
|
| Pratima Kumari, Priyanka Debta, Anshuman Dixit | | Frontiers in Pharmacology. 2022; 13 | | [Pubmed] | [DOI] | | | 8 |
ANTIHYPERTENSIVES IN ORAL SUB MUCOSAL FIBROSIS |
|
| Deepak Narang, Prabhjot Kaur, Amandeep Singh | | GLOBAL JOURNAL FOR RESEARCH ANALYSIS. 2022; : 93 | | [Pubmed] | [DOI] | | | 9 |
Consensus guidelines on management of oral potentially malignant disorders |
|
| PraveenN Birur, Sanjana Patrick, Saman Warnakulasuriya, Keerthi Gurushanth, ShubhasiniA Raghavan, GouraK Rath, Pankaj Chaturvedi, Vijay Chandru, Babu Mathew, Kumar Prabhash, Shubha Gurudath, Nirza Mukhia, SumsumP Sunny, Ravi Mehrotra, V Vivek, Shankargouda Patil, GSuresh Kumar, Shruthi Fasalkar, Rao Pratima, MoniA Kuriakose | | Indian Journal of Cancer. 2022; 0(0): 0 | | [Pubmed] | [DOI] | | | 10 |
Effect of trans retinoic acid on patients with oral submucous fibrosis-randomized single-blind monocentric study |
|
| Amit Gupta, Sanjeev Kumar, Pallavi Srivastava, VidhiC Rathi, Susmita Saxena, Anju Aggarwal | | Journal of Oral and Maxillofacial Pathology. 2021; 25(3): 411 | | [Pubmed] | [DOI] | | | 11 |
Regulation of Collagen Synthesis in Tobacco/Pan-Masala Induced Oral Sub-Mucosal Fibrosis and Diagnostic Approach - Review Article |
|
| Shraddha Awasthi, Ausaf Ahmad, Anand Narain Srivastava | | International Journal of Scientific Research in Science and Technology. 2021; : 134 | | [Pubmed] | [DOI] | | | 12 |
Potential Application of an Aqueous Extract of Tinospora Cordifolia (Thunb.) Miers (Giloy) in Oral Submucous Fibrosis—An In Vitro Study |
|
| Shankargouda Patil | | Materials. 2021; 14(12): 3374 | | [Pubmed] | [DOI] | | | 13 |
ORAL SUBMUCOUS FIBROSIS –A REVIEW |
|
| Manju. J, Priya Ramani, Rabitha . B | | GLOBAL JOURNAL FOR RESEARCH ANALYSIS. 2021; : 82 | | [Pubmed] | [DOI] | | | 14 |
Oral submucous fibrosis: An overview of a challenging entity |
|
| Sonia Gupta, Manveen Kaur Jawanda | | Indian Journal of Dermatology, Venereology and Leprology. 2021; 87: 768 | | [Pubmed] | [DOI] | | | 15 |
Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action |
|
| Evangelos Karatzas, Andrea C. Kakouri, George Kolios, Alex Delis, George M. Spyrou, Christina Chan | | PLOS ONE. 2021; 16(4): e0249687 | | [Pubmed] | [DOI] | | | 16 |
Comparative evaluation of efficacy of muscle relaxant, vasodilator and combined intralesional steroid with hyalaronidase use in oral submucous fibrosis |
|
| Zafar Saleem, Shivesh Kumar, Amit Kumar Rana | | IP Journal of Otorhinolaryngology and Allied Science. 2021; 4(3): 83 | | [Pubmed] | [DOI] | | | 17 |
Post exenteration prosthetic rehabilitation in mucormycosis cases: Tips and tricks |
|
| Sachin Gupta | | IP International Journal of Ocular Oncology and Oculoplasty. 2021; 7(3): 233 | | [Pubmed] | [DOI] | | | 18 |
Comparative study of rebamipide & betamethasone in managing stomatopyrosis in oral submucous fibrosis (OSMF) patients |
|
| Md. Asdullah, Nasir A Salati, Masood H Khan, R K Tiwari, Pradhuman Verma, Anshul Aggarwal | | Journal of Oral Medicine, Oral Surgery, Oral Pathology and Oral Radiology. 2021; 7(3): 157 | | [Pubmed] | [DOI] | | | 19 |
Oral submucous fibrosis and heterogeneity in outcome measures: a critical viewpoint |
|
| Sachin C Sarode, Shailesh Gondivkar, Amol Gadbail, Gargi S Sarode, Monal Yuwanati | | Future Oncology. 2021; 17(17): 2123 | | [Pubmed] | [DOI] | | | 20 |
Vaginal necrosis: A rare late toxicity after radiation therapy |
|
| Angela Y. Jia, Akila N. Viswanathan | | Gynecologic Oncology. 2021; 160(2): 602 | | [Pubmed] | [DOI] | | | 21 |
A clinicobiochemical evaluation of curcumin as gel and as buccal mucoadhesive patches in the management of oral submucous fibrosis |
|
| Aditi Chandrashekar, Rajeshwari G. Annigeri, Usha VA, J. Thimmasetty | | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2021; 131(4): 428 | | [Pubmed] | [DOI] | | | 22 |
Hypothesizing the therapeutic potential of mesenchymal stem cells in oral submucous fibrosis |
|
| Supriya Kheur, Avinash Sanap, Avinash Kharat, Archana A. Gupta, A. Thirumal Raj, Mohit Kheur, Ramesh Bhonde | | Medical Hypotheses. 2020; 144: 110204 | | [Pubmed] | [DOI] | | | 23 |
Efficacy of betamethasone, hyaluronidase and its combination on mouth opening, burning sensation and QOL in patients with OSF |
|
| Mohd Saalim, Kaustubh Sansare, Ibrahim K. Ali, Heena Sonawane, Neha Singla, Kavita Vanga, Ruchika Kapoor, Freny R. Karjodkar | | Journal of Oral Biology and Craniofacial Research. 2020; 10(4): 492 | | [Pubmed] | [DOI] | | | 24 |
Medicinal management of oral submucous fibrosis in the past decade- A systematic review |
|
| Chandramani B. More, Deepa Jatti Patil, Naman R. Rao | | Journal of Oral Biology and Craniofacial Research. 2020; 10(4): 552 | | [Pubmed] | [DOI] | | | 25 |
Surgical management of oral submucous fibrosis with “Seagull-nasolabial flap” combined with short-term oral pentoxifylline for preventing relapse |
|
| Y. Kholakiya, A. Jose, A. Rawat, S.A. Nagori, S. Jacob, A. Roychoudhury | | Journal of Stomatology, Oral and Maxillofacial Surgery. 2020; 121(5): 512 | | [Pubmed] | [DOI] | | | 26 |
Oral submucous fibrosis: a contemporary narrative review with a proposed inter-professional approach for an early diagnosis and clinical management |
|
| Naman R. Rao, Alessandro Villa, Chandramani B. More, Ruwan D. Jayasinghe, Alexander Ross Kerr, Newell W. Johnson | | Journal of Otolaryngology - Head & Neck Surgery. 2020; 49(1) | | [Pubmed] | [DOI] | | | 27 |
Effect of Areca Nut on Oral Health: A Review |
|
| M Shirzaiy, F Neshat | | Journal of Research in Dental and Maxillofacial Sciences. 2020; 5(3): 1 | | [Pubmed] | [DOI] | | | 28 |
Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments |
|
| Yen-Wen Shen, Yin-Hwa Shih, Lih-Jyh Fuh, Tzong-Ming Shieh | | International Journal of Molecular Sciences. 2020; 21(19): 7231 | | [Pubmed] | [DOI] | | | 29 |
Oral Submucous Fibrosis: A Review on Etiopathogenesis, Diagnosis, and Therapy |
|
| Yin-Hwa Shih,Tong-Hong Wang,Tzong-Ming Shieh,Yu-Hsin Tseng | | International Journal of Molecular Sciences. 2019; 20(12): 2940 | | [Pubmed] | [DOI] | | | 30 |
Oral Submucous Fibrosis: A Review on Etiopathogenesis, Diagnosis, and Therapy |
|
| Yin-Hwa Shih,Tong-Hong Wang,Tzong-Ming Shieh,Yu-Hsin Tseng | | International Journal of Molecular Sciences. 2019; 20(12): 2940 | | [Pubmed] | [DOI] | | | 31 |
Comparative Evaluation of Mitochondrial Antioxidants in Oral Potentially Malignant Disorders |
|
| SUMITA BANERJEE, SAIKAT MUKHERJEE, SANJIB MITRA, PALLAV SINGHAL | | The Kurume Medical Journal. 2019; 66(1): 15 | | [Pubmed] | [DOI] | | | 32 |
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases |
|
| Feng Liu,George Bayliss,Shougang Zhuang | | Clinical Science. 2019; 133(12): 1309 | | [Pubmed] | [DOI] | | | 33 |
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases |
|
| Feng Liu,George Bayliss,Shougang Zhuang | | Clinical Science. 2019; 133(12): 1309 | | [Pubmed] | [DOI] | | | 34 |
Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis |
|
| J Liu,F Chen,Z Wei,M Qiu,Z Li,H Dan,Q Chen,L Jiang | | Oral Diseases. 2018; 24(5): 706 | | [Pubmed] | [DOI] | | | 35 |
Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis |
|
| J Liu,F Chen,Z Wei,M Qiu,Z Li,H Dan,Q Chen,L Jiang | | Oral Diseases. 2018; 24(5): 706 | | [Pubmed] | [DOI] | | | 36 |
Conservative management of Oral Submucous Fibrosis in early and intermediate stage |
|
| Sachin Rai,Vidya Rattan,Akshat Gupta,Praveen Kumar | | Journal of Oral Biology and Craniofacial Research. 2018; 8(2): 86 | | [Pubmed] | [DOI] | | | 37 |
Pentoxifylline Therapy in the Management of Oral Submucous Fibrosis – A Review
|
|
| Vezhavendhan N, Sivaramakrishnan M, Khaaviya N, Fahmitha Parveen S | | Journal of Scientific Dentistry. 2018; 8(1): 19 | | [Pubmed] | [DOI] | | | 38 |
Use of pentoxifylline and tocopherol in radiation-induced fibrosis and fibroatrophy |
|
| V. Patel,M. McGurk | | British Journal of Oral and Maxillofacial Surgery. 2017; 55(3): 235 | | [Pubmed] | [DOI] | | | 39 |
Use of pentoxifylline and tocopherol in radiation-induced fibrosis and fibroatrophy |
|
| V. Patel,M. McGurk | | British Journal of Oral and Maxillofacial Surgery. 2017; 55(3): 235 | | [Pubmed] | [DOI] | | | 40 |
Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview |
|
| Wei Xiong Wen,Siang Yin Lee,Rafaella Siang,Rhun Yian Koh | | Advances in Therapy. 2017; 34(6): 1245 | | [Pubmed] | [DOI] | | | 41 |
Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview |
|
| Wei Xiong Wen,Siang Yin Lee,Rafaella Siang,Rhun Yian Koh | | Advances in Therapy. 2017; 34(6): 1245 | | [Pubmed] | [DOI] | | | 42 |
Current protocols in the management of oral submucous fibrosis: An update |
|
| Gururaj Arakeri,Kirthi Kumar Rai,George Boraks,Shekar Gowda Patil,Abdulsalam S. Aljabab,M.A.W. Merkx,Marco Carrozzo,Peter A. Brennan | | Journal of Oral Pathology & Medicine. 2017; 46(6): 418 | | [Pubmed] | [DOI] | | | 43 |
Current protocols in the management of oral submucous fibrosis: An update |
|
| Gururaj Arakeri,Kirthi Kumar Rai,George Boraks,Shekar Gowda Patil,Abdulsalam S. Aljabab,M.A.W. Merkx,Marco Carrozzo,Peter A. Brennan | | Journal of Oral Pathology & Medicine. 2017; 46(6): 418 | | [Pubmed] | [DOI] | | | 44 |
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update |
|
| Yung-Ming Chen,Wen-Chih Chiang,Shuei-Liong Lin,Tun-Jun Tsai | | Journal of Biomedical Science. 2017; 24(1) | | [Pubmed] | [DOI] | | | 45 |
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update |
|
| Yung-Ming Chen,Wen-Chih Chiang,Shuei-Liong Lin,Tun-Jun Tsai | | Journal of Biomedical Science. 2017; 24(1) | | [Pubmed] | [DOI] | | | 46 |
Oral submucous fibrosis: a review of the current management and possible directions for novel therapies |
|
| Saman Warnakulasuriya,A. Ross Kerr | | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2016; 122(2): 232 | | [Pubmed] | [DOI] | | | 47 |
Oral submucous fibrosis: a review of the current management and possible directions for novel therapies |
|
| Saman Warnakulasuriya,A. Ross Kerr | | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2016; 122(2): 232 | | [Pubmed] | [DOI] | | | 48 |
Clinicobiochemical evaluation of turmeric with black pepper and nigella sativa in management of oral submucous fibrosis—a double-blind, randomized preliminary study |
|
| Pratik R. Pipalia,Rajeshwari G. Annigeri,Ranjeeta Mehta | | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2016; 122(6): 705 | | [Pubmed] | [DOI] | | | 49 |
Clinicobiochemical evaluation of turmeric with black pepper and nigella sativa in management of oral submucous fibrosis—a double-blind, randomized preliminary study |
|
| Pratik R. Pipalia,Rajeshwari G. Annigeri,Ranjeeta Mehta | | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2016; 122(6): 705 | | [Pubmed] | [DOI] | | | 50 |
RECENT CONCEPTS OF ETIOPATHOGENESIS AND MANAGEMENT OF ORAL SUBMUCOUS FIBROSIS: A REVIEW OF LITERATURE |
|
| Priyankar Singh | | Journal of Evolution of Medical and Dental Sciences. 2015; 4(78): 13728 | | [Pubmed] | [DOI] | | | 51 |
Comparative evaluation of natural antioxidants spirulina and aloe vera for the treatment of oral submucous fibrosis |
|
| Santosh Patil,Bader Kureyem Al-Zarea,Sneha Maheshwari,Rohit Sahu | | Journal of Oral Biology and Craniofacial Research. 2015; | | [Pubmed] | [DOI] | | | 52 |
Management for premalignant lesions of the oral cavity |
|
| Aru Panwar,Robert Lindau,Aaron Wieland | | Expert Review of Anticancer Therapy. 2014; 14(3): 349 | | [Pubmed] | [DOI] | | | 53 |
Management for premalignant lesions of the oral cavity |
|
| Aru Panwar,Robert Lindau,Aaron Wieland | | Expert Review of Anticancer Therapy. 2014; : 1 | | [Pubmed] | [DOI] | | | 54 |
Evaluation of Medicinal Interventions for the Management of Oral Submucous Fibrosis: A Systematic Review of the Literature |
|
| Kamran Habib Awan, Syed Rashid Habib, Ana Pejcic, Rosnah Binti Zain | | The Journal of Contemporary Dental Practice. 2014; 15(6): 812 | | [Pubmed] | [DOI] | | | 55 |
Morphometric analysis of the mucosal vasculature in oral submucous fibrosis and its comparison with oral squamous cell carcinoma |
|
| Vinita V. Murgod,Alka D. Kale,Punnya V. Angadi,Seema Hallikerimath | | Journal of Oral Science. 2014; 56(2): 173 | | [Pubmed] | [DOI] | | | 56 |
Morphometric analysis of the mucosal vasculature in oral submucous fibrosis and its comparison with oral squamous cell carcinoma |
|
| Vinita V. Murgod,Alka D. Kale,Punnya V. Angadi,Seema Hallikerimath | | Journal of Oral Science. 2014; 56(2): 173 | | [Pubmed] | [DOI] | | | 57 |
Pathogenesis and therapeutic intervention of oral submucous fibrosis |
|
| ThukanaykanpalayamRagunathan Yoithapprabhunath, Thangadurai Maheswaran, Janardhanam Dineshshankar, Abraham Anusushanth, Pandian Sindhuja, Govindasamy Sitra | | Journal of Pharmacy And Bioallied Sciences. 2013; 5(5): 85 | | [Pubmed] | [DOI] | | | 58 |
Medical management of oral submucous fibrosis: An update |
|
| Martin Richa,Martin Vibha,Niharika Swain | | Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2013; 25(2): 151 | | [Pubmed] | [DOI] | | | 59 |
Oral submucous fibrosis: an overview of the aetiology, pathogenesis, classification, and principles of management |
|
| Gururaj Arakeri,Peter A. Brennan | | British Journal of Oral and Maxillofacial Surgery. 2013; 51(7): 587 | | [Pubmed] | [DOI] | | | 60 |
Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis |
|
| Chetan J. Bhadage,Hemant R. Umarji,Karan Shah,Hannamari Välimaa | | Clinical Oral Investigations. 2013; 17(5): 1375 | | [Pubmed] | [DOI] | | | 61 |
Pathogenesis and therapeutic intervention of oral submucous fibrosis |
|
| Yoithapprabhunath, T.R. and Maheswaran, T. and Dineshshankar, J. and Anusushanth, A. and Sindhuja, P. and Sitra, G. | | Journal of Pharmacy and Bioallied Sciences. 2013; 5(SUPPL.1): S85-S88 | | [Pubmed] | | | 62 |
Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis |
|
| Bhadage, C.J. and Umarji, H.R. and Shah, K. and Välimaa, H. | | Clinical Oral Investigations. 2013; 17(5): 1375-1382 | | [Pubmed] | | | 63 |
Medical management of oral submucous fibrosis: An update |
|
| Richa and Vibha and Swain, N. | | Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2013; 25(2): 151-156 | | [Pubmed] | | | 64 |
Pentoxifylline use in dermatology |
|
| Çakmak, S.K. and Çakmak, A. and Gönül, M. and Kiliç, A. and Gül, Ü. | | Inflammation and Allergy - Drug Targets. 2012; 11(6): 422-432 | | [Pubmed] | | | 65 |
Aloe vera in the treatment for oral submucous fibrosis - a preliminary study |
|
| Sudarshan, R. and Annigeri, R.G. and Vijayabala, G.S. | | Journal of Oral Pathology and Medicine. 2012; 41(10): 755-761 | | [Pubmed] | | | 66 |
Aloe vera in the treatment for oral submucous fibrosis - a preliminary study |
|
| Ramachandran Sudarshan,Rajeshwari G. Annigeri,G. Sree Vijayabala | | Journal of Oral Pathology & Medicine. 2012; 41(10): 755 | | [Pubmed] | [DOI] | | | 67 |
Comparative Study of Intralesional Triamcinolone Acetonide and Hyaluronidase vs Placental Extract in 60 Cases of Oral Submucous Fibrosis |
|
| Sudhir Naik, Sarika S Naik, S Ravishankara, Mohan K Appaji, MK Goutham, Nonthombam Pinky Devi, Annapurna S Mushannavar | | International Journal of Head and Neck Surgery. 2012; 3(2): 59 | | [Pubmed] | [DOI] | | | 68 |
A systematic review of medical interventions for oral submucous fibrosis and future research opportunities : Oral submucous fibrosis, medical management |
|
| | | Oral Diseases. 2011; 17: 42 | | [VIEW] | [DOI] | | | 69 |
Review of drug treatment of oral submucous fibrosis |
|
| | | Oral Oncology. 2011; | | [VIEW] | [DOI] | | | 70 |
Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice |
|
| Tonny W. Naranjo,Damaris E. Lopera,Lucy R. Diaz-Granados,Jhon J. Duque,Angela Restrepo M,Luz E. Cano | | Pulmonary Pharmacology & Therapeutics. 2011; 24(1): 81 | | [Pubmed] | [DOI] | | | 71 |
Pentoxifylline therapy in the management of oral submucous fibrosis |
|
| Mehrotra, R. and Singh, H.P. and Gupta, S.C. and Singh, M. and Jain, S. | | Asian Pacific Journal of Cancer Prevention. 2011; 12(4): 971-974 | | [Pubmed] | | | 72 |
A systematic review of medical interventions for oral submucous fibrosis and future research opportunities |
|
| Kerr, A. and Warnakulasuriya, S. and Mighell, A. and Dietrich, T. and Nasser, M. and Rimal, J. and Jalil, A. and Bornstein, M. and Nagao, T. and Fortune, F. and Hazarey, V. and Reichart, P. and Silverman, S. and Johnson, N. | | Oral Diseases. 2011; 17(SUPPL. 1): 42-57 | | [Pubmed] | | | 73 |
Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice |
|
| Naranjo, T.W., Lopera, D.E., Diaz-Granados, L.R., Duque, J.J., Restrepo M, A., Cano, L.E. | | Pulmonary Pharmacology and Therapeutics. 2011; 24(1): 81-91 | | [Pubmed] | | | 74 |
Children eating pan masala-beware of oral submucous fibrosis |
|
| Mehrotra, V., Tandon, V.K., Devi, P., Thimmarasa, V.B., Gupta, M. | | Indian Journal of Practical Pediatrics. 2011; 13(1): 100-104 | | [Pubmed] | | | 75 |
A Brief Review of Common Oral Premalignant Lesions with Emphasis on Their Management and Cancer Prevention |
|
| Sunitha Carnelio, Gabriel Sunil Rodrigues, Rajgopal Shenoy, Donald Fernandes | | Indian Journal of Surgery. 2011; | | [VIEW] | [DOI] | | | 76 |
Management of oral submucous fibrosis: an overview |
|
| Punnya V. Angadi, Sanjay Rao | | Oral and Maxillofacial Surgery. 2010; 14(3): 133 | | [VIEW] | [DOI] | | | 77 |
Oral submucosal fibrosis in Iran: A case review |
|
| Mansouri, P. and Yazdanian, S. and Safar, F. and Espandar, R. and Rezaii, S. and Safaie-Naraghi, Z. and Chalangari, R. | | International Journal of Dermatology. 2010; 49(12): 1424-1428 | | [Pubmed] | | | 78 |
Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis |
|
| Singh, M. and Niranjan, H.S. and Mehrotra, R. and Sharma, D. and Gupta, S.C. | | Indian Journal of Medical Research. 2010; 131(5): 665-669 | | [Pubmed] | | | 79 |
Coming to America betel nut and oral submucous fibrosis |
|
| Aziz, S.R. | | Journal of the American Dental Association. 2010; 141(4): 423-428 | | [Pubmed] | | | 80 |
Oral submucosal fibrosis in Iran: a case review : Oral submucosal fibrosis in Iran |
|
| Parvin Mansouri, Shideh Yazdanian, Farid Safar, Ramin Espandar, Samad Rezaii, Zahra Safaie-Naraghi, Reza Chalangari | | International Journal of Dermatology. 2010; 49(12): 1424 | | [VIEW] | [DOI] | | | 81 |
Coming to America |
|
| Shahid R. Aziz | | The Journal of the American Dental Association. 2010; 141(4): 423 | | [Pubmed] | [DOI] | | | 82 |
Correlation of histopathological diagnosis with habits and clinical findings in oral submucous fibrosis |
|
| Shruti Pandya, Ajay Kumar Chaudhary, Mamta Singh, Mangal Singh, Ravi Mehrotra | | Head & Neck Oncology. 2009; 1(1) | | [Pubmed] | [DOI] | | | 83 |
Influence of borneol on primary mice oral fibroblasts: a penetration enhancer may be used in oral submucous fibrosis |
|
| Jian-Ping Dai,Jun Chen,Yu-Fei Bei,Bang-Xing Han,Sheng Wang | | Journal of Oral Pathology & Medicine. 2009; 38(3): 276 | | [Pubmed] | [DOI] | | | 84 |
Drug Treatment of Oral Submucous Fibrosis: A Review of the Literature |
|
| Xiaowen Jiang,Jing Hu | | Journal of Oral and Maxillofacial Surgery. 2009; 67(7): 1510 | | [Pubmed] | [DOI] | | | 85 |
Head & Neck Oncology |
|
| Pandya, S. and Chaudhary, A.K. and Singh, M. and Singh, M. and Mehrotra, R. | | Head & Neck. 2009; 1: 10 | | [Pubmed] | | | 86 |
Correlation of histopathological diagnosis with habits and clinical findings in oral submucous fibrosis |
|
| Pandya, S. and Chaudhary, A.K. and Singh, M. and Singh, M. and Mehrotra, R. | | Head & Neck Oncology. 2009; 1: 10 | | [Pubmed] | | | 87 |
Influence of borneol on primary mice oral fibroblasts: a penetration enhancer may be used in oral submucous fibrosis. |
|
| Dai, J.P. and Chen, J. and Bei, Y.F. and Han, B.X. and Wang, S. | | Journal of Oral Pathology & Medicine. 2009; 38(3): 276-281 | | [Pubmed] | | | 88 |
Drug Treatment of Oral Submucous Fibrosis: A Review of the Literature |
|
| Jiang, X. and Hu, J. | | Journal of Oral and Maxillofacial Surgery. 2009; 67(7): 1510-1515 | | [Pubmed] | | | 89 |
Oral Submucous Fibrosis: Case Report and Review of Diagnosis and Treatment |
|
| Aziz, S.R. | | Journal of Oral and Maxillofacial Surgery. 2008; 66(11): 2386-2389 | | [Pubmed] | | | 90 |
Oral submucous fibrosis, a clinically benign but potentially malignant disease: Report of 3 cases and review of the literature |
|
| Auluck, A., Rosin, M.P., Zhang, L., Sumanth, K.N. | | Journal of the Canadian Dental Association. 2008; 74(8): 735-740 | | [Pubmed] | | | 91 |
Prevention and Treatment of Functional and Structural Radiation Injury in the Rat Heart by Pentoxifylline and Alpha-Tocopherol |
|
| Boerma, M. and Roberto, K.A. and Hauer-Jensen, M. | | International Journal of Radiation Oncology, Biology, Physics. 2008; 72(1): 170-177 | | [Pubmed] | | | 92 |
Interventions for the management of oral submucous fibrosis |
|
| Zbys Fedorowicz,Edwin Chan Shih-Yen,Mojtaba Dorri,Mona Nasser,Tim Newton,Luming Shi | | Cochrane Database of Systematic Reviews. 2008; | | [Pubmed] | [DOI] | | | 93 |
Interventions for the management of oral submucous fibrosis |
|
| Zbys Fedorowicz,Edwin Chan Shih-Yen,Mojtaba Dorri,Mona Nasser,Tim Newton,Luming Shi | | Cochrane Database of Systematic Reviews. 2008; | | [Pubmed] | [DOI] | | | 94 |
Prevention and Treatment of Functional and Structural Radiation Injury in the Rat Heart by Pentoxifylline and Alpha-Tocopherol |
|
| Marjan Boerma,Kerrey A. Roberto,Martin Hauer-Jensen | | International Journal of Radiation Oncology*Biology*Physics. 2008; 72(1): 170 | | [Pubmed] | [DOI] | | | 95 |
Oral Submucous Fibrosis: Case Report and Review of Diagnosis and Treatment |
|
| Shahid R. Aziz | | Journal of Oral and Maxillofacial Surgery. 2008; 66(11): 2386 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 32714 | | | Printed | 1812 | | | Emailed | 104 | | | PDF Downloaded | 8 | | | Comments | [Add] | | | Cited by others | 95 | | |
|
|
Users online:
